New combo therapy aims to control Tough-to-Treat blood cancer
NCT ID NCT05502250
Summary
This study is testing whether a drug called tislelizumab, when given with standard chemotherapy, can help control Hodgkin lymphoma that has come back or hasn't responded to initial treatment. The goal is to see if this approach works as well as the current intensive standard treatment, which involves high-dose chemotherapy and a stem cell transplant. The trial will measure how long patients live without their cancer getting worse and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BE-Bruxelles-STLUC
Brussels, Belgium
-
DK-Aarhus N-AUH
Aarhus, Denmark
-
DK-Copenhagen-RIGSHOSPITALET
Copenhagen, Denmark
-
DK-Odense-OUH
Odense, Denmark
-
NL-Amersfoort-MEANDERMC
Amersfoort, Netherlands
-
NL-Amsterdam-AMC
Amsterdam, Netherlands
-
NL-Arnhem-RIJNSTATE
Arnhem, Netherlands
-
NL-Den Haag-HAGA
The Hague, Netherlands
-
NL-Eindhoven-MAXIMAMC
Eindhoven, Netherlands
-
NL-Goes-ADRZ
Goes, Netherlands
-
NL-Groningen-UMCG
Groningen, Netherlands
-
NL-Hoofddorp-SPAARNEGASTHUIS
Hoofddorp, Netherlands
-
NL-Leeuwarden-MCL
Leeuwarden, Netherlands
-
NL-Maastricht-MUMC
Maastricht, Netherlands
-
NL-Rotterdam-ERASMUSMC
Rotterdam, Netherlands
Conditions
Explore the condition pages connected to this study.